TP53 and Miyoshi myopathy: Recently, a specific entity named the double-hit MM with del17p13 and TP53 mutation or 1q amplification (four or more copies) and International Staging System (ISS) stage 3 has been shown to have poor survival with median progression-free survival (PFS) of 15.4 months and median overall survival (OS) of 20.7 months [6].